BIOLINERX Ltd/S (NASDAQ:BLRX) PT Set at $4.00 by HC Wainwright

BIOLINERX Ltd/S (NASDAQ:BLRX) has been assigned a $4.00 target price by research analysts at HC Wainwright in a note issued to investors on Tuesday, August 7th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 330.11% from the company’s previous close.

BLRX has been the topic of a number of other reports. ValuEngine upgraded BIOLINERX Ltd/S from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Zacks Investment Research upgraded BIOLINERX Ltd/S from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research note on Friday, May 25th. Finally, MED began coverage on BIOLINERX Ltd/S in a research note on Wednesday, August 1st. They issued a “market perform” rating on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $2.50.

NASDAQ:BLRX traded up $0.01 during midday trading on Tuesday, reaching $0.93. The company had a trading volume of 414,800 shares, compared to its average volume of 396,130. The firm has a market cap of $94.51 million, a PE ratio of -3.41 and a beta of 0.50. BIOLINERX Ltd/S has a 12-month low of $0.78 and a 12-month high of $1.34.

An institutional investor recently raised its position in BIOLINERX Ltd/S stock. Renaissance Technologies LLC lifted its position in shares of BIOLINERX Ltd/S (NASDAQ:BLRX) by 60.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 434,700 shares of the biotechnology company’s stock after purchasing an additional 164,500 shares during the period. Renaissance Technologies LLC owned about 0.41% of BIOLINERX Ltd/S worth $474,000 at the end of the most recent reporting period. Institutional investors own 34.70% of the company’s stock.


BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Read More: Do closed-end mutual funds pay dividends?

Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with's FREE daily email newsletter.

Leave a Reply